Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Cyteir Therapeutics, Inc. (CYT)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-05-22Dec-31-21Dec-05-21Dec-31-20Dec-31-19
   8-K10-K8-K10-KS-1/A
Revenues  34.60.031.00.012.8
            Revenue growth  11.8%  -100.0% 
Cost of goods sold  48.20.042.30.025.5
Gross profit  -13.50.0-11.30.0-12.8
            Gross margin  -39.1% -36.5% -99.9%
Selling, general and administrative   [+]13.542.311.320.93.3
Other operating expenses  21.1-0.319.7-0.3 
EBITDA   [+] -41.5 -20.3-15.9
            EBITDA margin  -139.1% -136.5% -124.5%
Depreciation and amortization   0.5 0.40.2
EBIT   [+]-48.2-42.0-42.3-20.7-16.1
            EBIT margin  -139.1% -136.5% -126.1%
Other income (expense), net  2.1-0.10.1-0.11.1
Pre-tax income  -46.1-42.1-42.1-20.8-15.0
Income taxes  0.00.00.00.00.0
            Tax rate  0.0%0.0%0.0% 0.0%
Net income  -46.1-42.1-42.1-20.8-15.0
            Net margin  -133.0% -136.1% -117.8%
   
Basic EPS   [+]($1.31)($2.16)($2.16)($13.60)($0.01)
Diluted EPS   [+]($1.31)($2.16)($2.16)($13.60)($0.01)
   
Shares outstanding (basic)   [+]35.319.519.51.51,290.2
Shares outstanding (diluted)   [+]35.319.519.51.51,290.2
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy